The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy
Science Immunology · 28.07.2023 · 8 (85)
DOI: 10.1126/sciimmunol.abq3015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Science Immunology, erschienen am 28.07.2023. Verfasst von John Stagg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, 900 St-Denis street, Montreal, QC H2X 0A9, Canada. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The extracellular nucleoside adenosine reduces tissue inflammation and is generated by irreversible dephosphorylation of adenosine monophosphate (AMP) mediated by the ectonucleotidase CD73. The pro-inflammatory nucleotides adenosine triphosphate, nicotinamide adenine dinucleotide, and cyclic guanosine -monophosphate–AMP (cGAMP), which are produced in the tumor microenvironment (TME) during therapy-induced immunogenic cell death and activation of innate immune signaling, can be converted into AMP by ectonucleotidases CD39, CD38, and CD203a/ENPP1. Thus, ectonucleotidases shape the TME by converting immune-activating signals into an immunosuppressive one. Ectonucleotidases also hinder the ability of therapies including radiation therapy, which enhance the release of pro-inflammatory nucleotides in the extracellular milieu, to induce immune-mediated tumor rejection. Here, we review the immunosuppressive effects of adenosine and the role of different ectonucleotidases in modulating antitumor immune responses. We discuss emerging opportunities to target adenosine generation and/or its ability to signal via adenosine receptors expressed by immune and cancer cells in the context of combination immunotherapy and radiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, 900 St-Denis street, Montreal, QC H2X 0A9, Canada.
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA.
- Division of Radiotherapy and Imaging, Institute of Cancer Research, London SM2 5NG, UK.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
ORCID-Profile: John Stagg, Erik Wennerberg, Sandra Demaria
Förderung
- NCI NIH HHS
Zitieren
APA
Stagg, J., Golden, E., Wennerberg, E., & Demaria, S. (2023). The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy. Science Immunology, 8(85). https://doi.org/10.1126/sciimmunol.abq3015
Vancouver
Stagg J, Golden E, Wennerberg E, Demaria S. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy. Science Immunology. 2023;8(85). doi:10.1126/sciimmunol.abq3015
BibTeX
@article{Stagg2023,
author = {Stagg, John and Golden, Encouse and Wennerberg, Erik and Demaria, Sandra},
title = {The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy},
journal = {Science Immunology},
year = {2023},
volume = {8},
number = {85},
doi = {10.1126/sciimmunol.abq3015}
}
EUVIMED